ArticleNucleic acids research2018
Regulation of T cell proliferation with drug-responsive microRNA switches.
Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Repurposing Tumor Cells: A Paradigm Shift in Cell-Based Therapies for Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- RNA-based controllers for engineering gene and cell therapies.Current opinion in biotechnology · 2024Review
- Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.NPJ systems biology and applications · 2023Review
- RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes.Nature communications · 2023Article
- Dynamic RNA synthetic biology: new principles, practices and potential.RNA biology · 2023Review
- Premature translation termination mediated non-ER stress induced ATF6 activation by a ligand-dependent ribosomal frameshifting circuit.Nucleic acids research · 2022Article
- Engineering synthetic RNA devices for cell control.Nature reviews. Genetics · 2022Review
- Article
- Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.ACS pharmacology & translational science · 2021Review
- Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A multiplexed, automated evolution pipeline enables scalable discovery and characterization of biosensors.Nature communications · 2021Article
- The role of small molecules in cell and gene therapy.RSC medicinal chemistry · 2021Review
- Translational control of enzyme scavenger expression with toxin-induced micro RNA switches.Scientific reports · 2021Article
- High-throughput identification of synthetic riboswitches by barcode-free amplicon-sequencing in human cells.Nature communications · 2020Article
- Synthetic Biology Speeds Up Drug Target Discovery.Frontiers in pharmacology · 2020Review
- Aptamer-based and aptazyme-based riboswitches in mammalian cells.Current opinion in chemical biology · 2019Review
- Massively parallel RNA device engineering in mammalian cells with RNA-Seq.Nature communications · 2019Article
- Applications of molecular engineering in T-cell-based immunotherapies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Numerical operations in living cells by programmable RNA devices.Science advances · 2019Article
- Programmable mutually exclusive alternative splicing for generating RNA and protein diversity.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
As molecular and cellular therapies advance in the clinic, the role of genetic regulation is becoming increasingly important for controlling therapeutic potency and safety. The emerging field of mammalian synthetic biology provides promising tools for the construction of regulatory platforms that can intervene with endogenous pathways and control cell behavior. Recent work has highlighted the development of synthetic biological systems that integrate sensing of molecular signals to regulated therapeutic function in various disease settings. However, the toxicity and limited dosing of currently available molecular inducers have largely inhibited translation to clinical settings. In this work, we developed synthetic microRNA-based genetic systems that are controlled by the pharmaceutical drug leucovorin, which is readily available and safe for prolonged administration in clinical settings. We designed microRNA switches to target endogenous cytokine receptor subunits (IL-2Rβ and γc) that mediate various signaling pathways in T cells. We demonstrate the function of these control systems by effectively regulating T cell proliferation with the drug input. Each control system produced unique functional responses, and combinatorial targeting of multiple receptor subunits exhibited greater repression of cell growth. This work highlights the potential use of drug-responsive genetic control systems to improve the management and safety of cellular therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.